Advances in imaging for diagnosis and management of cardiac sarcoidosis

European Heart Journal Cardiovascular Imaging

Volumn 16, Issue 9, 2015, Pages 949-958

  Aggarwal, Niti R ^a   Snipelisky, David ^a   Young, Phillip M ^a   Gersh, Bernard J ^a   Cooper, Leslie T ^a,b   Chareonthaitawee, Panithaya ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Cardiac MRI; Cardiac PET imaging; Cardiac sarcoidosis; FDG PET imaging

Indexed keywords

BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; FLUORODEOXYGLUCOSE F 18; IMMUNOSUPPRESSIVE AGENT;

CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HOLTER MONITORING; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; JAPANESE (PEOPLE); POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SARCOIDOSIS; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SURVIVAL; AMBULATORY ELECTROCARDIOGRAPHY; CARDIOMYOPATHIES; CAUSE OF DEATH; CINE MAGNETIC RESONANCE IMAGING; COMPARATIVE STUDY; COMPUTER ASSISTED DIAGNOSIS; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; FEMALE; FORECASTING; IMAGE ENHANCEMENT; MALE; MASS SCREENING; MORTALITY; PROCEDURES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TRENDS;

CARDIAC IMAGING TECHNIQUES; CARDIOMYOPATHIES; CAUSE OF DEATH; DISEASE-FREE SURVIVAL; EARLY DIAGNOSIS; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; FLUORODEOXYGLUCOSE F18; FORECASTING; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING, CINE; MALE; MASS SCREENING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOGRAPHIC IMAGE ENHANCEMENT; RISK ASSESSMENT; SARCOIDOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 84989195926     PISSN: 20472404     EISSN: 20472412     Source Type: Journal    
DOI: 10.1093/ehjci/jev142     Document Type: Review

References (36)

1. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007;357: 2153-65.
2. Zipse MM, Sauer WH. Cardiac sarcoidosis. Curr Cardiol Rep 2014;16:514.
3. Lynch JP, Hwang J, Bradfield J, Fishbein M, Shivkumar K, Tung R. Cardiac involvement in sarcoidosis: Evolving concepts in diagnosis and treatment. Semin Respir Crit Care Med 2014;35:372-90.
4. Orii M, Imanishi T, Akasaka T. Assessment of cardiac sarcoidosis with advanced imaging modalities. BioMed Res Int 2014;2014:15.
5. Mehta D, Lubitz SA, Frankel Z, Wisnivesky JP, Einstein AJ, Goldman M et al. Cardiac involvement in patients with sarcoidosis: Diagnostic and prognostic value of outpatient testing. Chest 2008;133:1426-35.
6. Kandolin R, Lehtonen J, Airaksinen J, Vihinen T, Miettinen H, Ylitalo K et al. Cardiac sarcoidosis: Epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation 2015;131:624-32.
7. Yazaki Y, Isobe M, Hiroe M, Morimoto S-i, Hiramitsu S, Nakano T et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001;88:1006-10.
8. Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis Granulomatous Disord 2007;27:89-102.
9. Judson MB, Baughman RP, Teirstein AS, Terrin ML, Yeager H Jr. Defining organ involvement in sarcoidosis: The ACCESS proposed instrument. ACCESS research group. A case control etiologic study of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:75-86.
10. Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11:1305-24.
11. Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States: A Delphi study. Chest 2012;141:154-62.
12. Joyce E, Ninaber MK, Katsanos S, Debonnaire P, Kamperidis V, Bax JJ et al. Subclinical left ventricular dysfunction by echocardiographic speckle-tracking strain analysis relates to outcome in sarcoidosis. Eur J Heart Fail 2014;17:51-62.
13. Yazaki Y, Isobe M, Hiramitsu S, Morimoto SI, Hiroe M, Omichi C et al. Comparison of clinical features and prognosis of cardiac sarcoidosis and idiopathic dilated cardiomyopathy. Am J Cardiol 1998;82:537-40.
14. Aggeli C, Felekos I, Tousoulis D, Gialafos E, Rapti A, Stefanadis C. Myocardial mechanics for the early detection of cardiac sarcoidosis. Int J Cardiol 2013;168:4820-1.
15. Bulkley BH, Rouleau JR, Whitaker JQ, Strauss HW, Pitt B. The use of 201-thallium for myocardial perfusion imaging in sarcoid heart disease. Chest 1977;72:27-32.
16. Eguchi M, Tsuchihashi K, Hotta D, Hashimoto A, Sasao H, Yuda S et al. Technetium-99m sestamibi/tetrofosmin myocardial perfusion scanning in cardiac and noncardiac sarcoidosis. Cardiology 2000;94:193-9.
17. Caldwell JW. Do thallium myocardial perfusion scan abnormalities predict survival in sarcoid patients without cardiac symptoms? Angiology 1990;41:573-6.
18. Kinney EL, Jackson GL, Reeves WC, Zelis R. Thallium-scan myocardial defects and echocardiographic abnormalities in patients with sarcoidosis without clinical cardiac dysfunction. An analysis of 44 patients. Am J Med 1980;68:497-503.
19. Yamagishi H, Shirai N, Takagi M, Yoshiyama M, Akioka K, Takeuchi K et al. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. J Nucl Med 2003; 44:1030-6.
20. Nakazawa A, Ikeda K, Ito Y, Iwase M, Sato K, Ueda R et al. Usefulness of dual 67Ga and 99mTc-sestamibi single-photon-emission CT scanning in the diagnosis of cardiac sarcoidosis. Chest 2004;126:1372-6.
21. OkumuraW, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004;45: 1989-98.
22. Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakaue S, KamigakiMet al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005;26:1538-43.
23. Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008;35:933-41.
24. Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18F-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009;16: 801-10.
25. Tahara N, Tahara A, Nitta Y, Kodama N, Mizoguchi M, Kaida H et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging 2010;3:1219-28.
26. Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;63:329-36.
27. Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: A systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012;53:241-8.
28. Smedema J-P, Snoep G, van Kroonenburgh MPG, van Geuns R-J, Dassen WRM, Gorgels APM et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005;45:1683-90.
29. Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, JaroudiWA et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969-77.
30. Maurer AH, Burshteyn M, Adler LP, Gaughan JP, Steiner RM. Variable cardiac 18FDG patterns seen in oncologic positron emission tomography computed tomography importance for differentiating normal physiology from cardiac and paracardiac disease. J Thorac Imaging 2012;27:263-8.
31. Mc Ardle BA, Birnie DH, Klein R, de Kemp RA, Leung E, Renaud J et al. Is there an association between clinical presentation and the location and extent of myocardial involvement of cardiac sarcoidosis as assessed by 18F-fluorodoexyglucose positron emission tomography? Circulation 2013;6:617-26.
32. Crouser ED, Ono C, Tran T, He X, Raman SV. Improved detection of cardiac sarcoidosis using magnetic resonance with myocardial T2 mapping. Am J Respir Crit Care Med 2014;189:109-12.
33. Vignaux O, Dhote R, Duboc D, Blanche P, Dusser D, Weber S et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: A 1-year follow-up study. Chest 2002;122:1895-901.
34. Greulich S, Deluigi CC, Gloekler S, Wahl A, Zürn C, Kramer U et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 2013;6:501-11.
35. Crawford T, Sarsam S, Mueller G, Gupta S, Baman T, Ilg K et al. The role of magnetic resonance imaging in identifying patients with cardiac sarcoidosis and preserved left ventricular function in predicting future ventricular arrhythmias. J Am Coll Cardiol 2012;59(Suppl. 1):E575 (Presented at 61th Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention, ACC.12 Chicago, IL, USA).
36. White JA, Rajchl M, Butler J, Thompson RT, Prato FS, Wisenberg G. Active cardiac sarcoidosis: First clinical experience of simultaneous positron emission tomography- magnetic resonance imaging for the diagnosis of cardiac disease. Circulation 2013;127:e639-e41.